Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
MERS-CoV diagnosis: An update

Sameera Al Johani*, Ali H. Hajeer

Department of Pathology and Laboratory Medicine, King Saud University for Health Sciences, Riyadh, Saudi Arabia

Received 4 April 2016; accepted 5 April 2016

Summary Diagnosis of MERS-CoV still a major concern in most of diagnostic laboratories. To date the Real-time Polymerase Chain reaction (RT-PCR) is the mainstay for diagnosis of MERS-CoV. RT-PCR has limitations, including a long turnaround time and lack of common measurements and correlations with Viral Load (VL). It is recommended to screen for MERS-CoV using RT-PCR of the upstream of envelope gene (upE) followed by confirmation of the presence of one of the following genes; open reading frame 1A, 1B genes or nucleocapsid (N) gene. Scientists are looking to implement viral sequencing on all negative samples by RT-PCR and they believe that can be exposed to another level of testing using sequencing of the RNA-dependent RNA polymerase (RdRp) gene or N gene and in this case a positive result is diagnostic. It is also very important to maintain a continuous and random sequencing for MERS-CoV samples to be able to pick early viral mutations. Serological assays still not widely or routinely performed, and a lot of studies looking to implement such method in routine patient’s tests.

© 2016 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Limited. All rights reserved.

Three years have passed since the discovery of the newly emerging coronavirus namely Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and many questions are still unanswered. We will summarize the latest diagnostic testing for confirmation of a case with MERS-CoV infection raising some questions that are still unanswered.

Sampling

Detecting the virus in respiratory tract samples remains the gold standard in diagnosing MERS-CoV infection. Several samples can be obtained from the respiratory system that can be used for diagnosing MERS-CoV infection. These include tracheal aspirates, nasopharyngeal swabs, bronchoalveolar
lavage and sputum. Tracheal aspirates and bronchoalveolar lavage samples (lower respiratory samples) yielded significantly higher viral copies than nasopharyngeal and sputum samples [1]. Analyzing whole blood and plasma also yielded positive viral genome [2]. The kinetics of viral presence in blood is not well understood. The observation of lymphopenia in severe cases and the presence of the virus receptor on naïve and memory T lymphocytes [3] warrant the study of viral replication inside T lymphocytes.

PCR

To date the Real-time Polymerase Chain reaction (RT-PCR) is the mainstay for diagnosis of MERS-CoV. RT-PCR has limitations, including a long turnaround time (chiefly due to transportation of virus and test preparation), and lack of common measurements and correlations with Viral Load (VL). Most laboratories are determining only cycle threshold (Ct) values (which are inversely related to virus load) as a predictor for VL, disease progression and as a cut off marker in order to diagnose cases. Yet, few studies have evaluated whether cycle threshold (Ct) values are associated with clinical severity [4].

It is recommended to screen for MERS-CoV using RT-PCR of the upstream of envelope gene (upE) followed by confirmation of the presence of one of the following genes; open reading frame 1A, 1B genes or nucleocapsid (N) gene [5]. Negative samples by RT-PCR can be exposed to another level of testing using sequencing of the RNA-dependent RNA polymerase (RdRp) gene or N gene [5] and in this case a positive result is diagnostic. Commercially available kits utilizing this algorithm were tested and found to be highly sensitive and specific [6].

Quality of reported results should be maintained at all times. Part of the quality programs available is the external proficiency testing. This method was applied locally during the Korean outbreak [7] and later at a wider level [8].

Seong et al. [10] also sequenced MERS-CoV viral genomes from four Korean patients during the May–July 2015 outbreak. There was no evidence of substantial evolutionary change in the virus compared to Middle Eastern sequences. Borucki et al. [11] used deep sequencing on nasal samples of three camels that were infected with MERS-CoV and found only 5 mutations in the consensus sequences. Yet, any mutations could potentially influence the virus phenotype and impact the detection of the virus by molecular assays.

Assiri et al. [12] sequenced MERS-CoV spike gene in an outbreak in Taif. Phylogenetic analysis of their samples revealed a cluster located within the Hafr-Al-Batin clade and were closely related to viruses isolated from Riyadh during 2013 and 2014 outbreaks. They also identified five unique nucleotide substitutions in the spike protein [12]. Whereas, Kim et al. [13] found mutations in the receptor binding domain of the S protein in 12 out of 13 MERS-CoV isolates from Korea resulting in reduced affinity to the human receptor CD26.

These data suggest that sequencing of MERS-CoV is likely warranted for any new and subsequent outbreaks. Changes that may affect the virulence of the virus. In addition, it will be important to observe the location of new mutations in the virus genes and in order to attempt to predict effects on primer and probe binding sites, which may influence diagnostic ability of the currently available commercial kits.

Serology testing

As with other acute viruses, detection of antibodies and even antigens might lag sometime after the detection of viral genome by molecular methods. The kinetics of antigen production in the nasopharyngeal samples has not been studied so far. However, antibodies to the virus generally appear after 10 days of the illness onset. In severely ill patients requiring mechanical ventilation, antibodies were delayed further [14].

An ELISA capture assay to detect NP antigens of the MERS-CoV virus in nasopharyngeal samples was developed recently [15]. The assay was highly sensitive (detection of the MERS-CoV-NP of less than 1 ng/mL) and specific (specificity of 100%) for MERS-CoV and has the potential to be used in animals as well. Song et al. developed a rapid immunochromatographic assay for the detection of MERS-CoV nucleocapsid protein from camel nasal swabs with 93.9% sensitivity and 100% specificity compared to RT-rtPCR. The assay is very promising and worth
replication in both camel and humans. As yet, anti-
gen detection assays are not widely available; yet
this type of assays will ideally be valuable in ruling
infection in, and out.
MERS-CoV is very similar to SARS, both are beta-
coronaviruses; and in both cases the S and N
proteins are very immunogenic and good candidates
for developing an immune assay for the detection
of virus specific antibodies [16]. Several assays
have been developed to detect antibodies to MERS-
CoV; including neutralization assays, ELISA and
IFA.
Perera et al. [17] developed a microneutral-
ization assay to detect specific anti-MERS-CoV
antibodies. They used serial dilution of serum which
was incubated with vero cells/MERS-CoV virus.
After three days at 37°C, they scored the anti-
body titers based on the virus CPE. In addition, they
developed a MERS-CoV spike pseudoparticle neu-
tralization assay [17]. They used HIV/MERS spike
pseudoparticles to infect Vero E6 cells, after 2 days
infected cells were lysed and the antibody that gave
90% luciferase reduction was assigned as ppNA anti-
body titer. Compared to virus neutralization assay,
the pseudoparticle neutralization assay does not
require BSL3 containment.
Indirect fluorescent antibody assay for the
detection of antibodies to MERS-CoV was carried
out using whole virus in vero cells [18,19] or
transfected Vero cells with spike or nucleocapsid
proteins of MERS-CoV [18]. ELISA utilizing S1 pro-
tein is also available and been used for investigating
epidemiology of the exposure to the virus [20]. So
far, there are no studies comparing ELISA for the
detection of anti-MERS-CoV antibodies with either
IFA or neutralization assays.
Detection of anti-MERS-CoV antibodies using
the different assays described above still requires
confirmation by the neutralization assays. Other
techniques are needed to support confirmation of
the antibody specificity, as neutralization assay is
not widely used. Western blotting has been used in
SARS [21] and other viruses to confirm antibody
specificity. There is a need for Western blotting
assay in case of MERS-CoV to confirm antibody
specificity. This can be in the form of genetically
engineered specific MERS-CoV antigens blotted on
membranes.
In summary, molecular techniques are the first
line of assays to be used for confirmation of
MERS-CoV infection. Tracheal aspirates and bron-
choalveolar lavage samples (lower respiratory
samples) are recommended for detecting the virus
by RT-PCR or sequencing. Serology is valuable con-
firming cases suspected for MERS-CoV but the virus
is not detected in respiratory samples.

Funding
No funding sources.

Competing interests
None declared.

Ethical approval
Not required.

References
[1] Memish ZA, Al-Tawfiq JA, Makhdoum HQ, Assiri A, Alha-
keem RF, Albarrak A, et al. Respiratory tract samples, viral
load, and genome fraction yield in patients with Middle East
respiratory syndrome. J Infect Dis 2014;210(10):1590–4.
[2] Guery B, Poissy J, el Mansouf L, Sejourne C, Ettahtar N,
Lemaire X, et al. Clinical features and viral diagnosis of two
cases of infection with Middle East respiratory syndrome
coronavirus: a report of nosocomial transmission. Lancet
2013;381(9885):2265–72.
[3] Ulmer AJ, Mattern T, Flad HD. Expression of CD26 (depe-
tidyl peptide dase IV) on memory and naive T lymphocytes.
Scand J Immunol 1992;35(5):551–9.
[4] Feikin DR, Alraddadi B, Qutub M, Shabouni O, Curns A,
Oboho I, et al. Association of higher MERS-CoV virus load
with severe disease and death, Saudi Arabia, 2014. Emerg
 Infect Dis 2015;21(11):2029–35.
[5] Laboratory testing for Middle East respiratory syndrome
coronavirus (MERS-CoV). http://apps.who.int/iris/bitsream/
bitstream/10665/176982/1/WHO_MERS_LAB_15.1_eng.pdf?
ua=1.
[6] Corman VM, Olschlager S, Wendtner CM, Drexlter JF, Hess M,
Drosten C. Performance and clinical validation of the Real-
Star MERS-CoV Kit for detection of Middle East respiratory
syndrome coronavirus RNA. J Clin Virol 2014;60(2):168–71.
[7] Seong MW, Lee SJ, Cho SI, Ko K, Kim MN, Sung H, et al.
External Quality Assessment of MERS-CoV molecular diag-
nostics during the 2015 Korean outbreak. Ann Lab Med
2016;36(3):230–4.
[8] Pas SD, Patel P, Reusken C, Domingo C, Corman VM,
Drosten C, et al. First international external quality assess-
ment of molecular diagnostics for Mers-CoV. J Clin Virol
2015;69:81–5.
[9] Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus
AD, Fouchier RA. Isolation of a novel coronavirus from
a man with pneumonia in Saudi Arabia. N Engl J Med
2012;367(19):1814–20.
[10] Seong MW, Kim SY, Corman VM, Kim TS, Cho SI, Kim MJ, et al.
Microevolution of outbreak-associated Middle East respira-
 tory syndrome coronavirus, South Korea, 2015. Emerg Infect
Dis 2016;22(2).
[11] Borucki MK, Lao V, Hwang M, Gardner S, Adney D, Mun-
ster V, et al. Middle East respiratory syndrome coronavirus
intra-host populations are characterized by numerous high
frequency variants. PLOS ONE 2016;11(1):e0146251.
[12] Assiri A, Abedi GR, Saeed AA, Abdalla MA, Al-Masyr M,
Choudhry AJ, et al. Multifacility outbreak of Middle East
respiratory syndrome in Taif, Saudi Arabia. Emerg Infect Dis 2016;22(1):32—40.

[13] Kim Y, Cheon S, Min CK, Sohn KM, Kang YJ, Cha YJ, et al. Spread of mutant Middle East respiratory syndrome coronavirus with reduced affinity to human CD26 during the South Korean outbreak. mBio 2016;7(2).

[14] Park WB, Perera RA, Choe PG, Lau EH, Choi SJ, Chun JY, et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg Infect Dis 2015;21(12):2186—9.

[15] Chen Y, Chan KH, Kang Y, Chen H, Luk H, Poon RW, et al. A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus. Emerg Microbes Infect 2015;4(4):e26.

[16] Meyer B, Drosten C, Muller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res 2014;194:175–83.

[17] Perera RA, Wang P, Gomaa MR, El-Shesheny R, Kandeil A, Bagato O, et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill 2013;18(36), pii:20574.

[18] Buchholz U, Muller MA, Nitsche A, Sanewski A, Wevering N, Bauer-Balci T, et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October—November 2012. Euro Surveill 2013;18(8).

[19] Corman VM, Muller MA, Costabel U, Timm J, Binger T, Meyer B, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012;17(49).

[20] Muller MA, Meyer B, Corman VM, Al-Masri M, Turkestani A, Ritz D, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis 2015;15(5):559–64.

[21] Wang YD, Li Y, Xu GB, Dong XY, Yang XA, Feng ZR, et al. Detection of antibodies against SARS-CoV in serum from SARS-infected donors with ELISA and Western blot. Clin Immunol 2004;113(2):145–50.